Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
U.S. FDA to decide whether to authorize a booster dose in the coming days
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Filing for WHO Emergency Use Authorisation this month
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
Five seats reserved for Wards of COVID warriors in central MBBS admission
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Subscribe To Our Newsletter & Stay Updated
